Skip to main content
Download PDF
- Main
Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study
- Camargo, Jose F;
- Lin, Rick Y;
- Natori, Yoichiro;
- Anderson, Anthony D;
- Alencar, Maritza C;
- Wang, Trent P;
- Morris, Michele I;
- Komanduri, Krishna V
Published Web Location
https://doi.org/10.1182/bloodadvances.2020002269Abstract
Key Points Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery. In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.